Handan Tongyi New Material Technology Co., Ltd

Pregabalin is an analogue of GABA, associated with gabapentin, and has been extensively studied in the treatment of generalized anxiety disorder, fibromyalgia, neuralgia, and partially complex epilepsy. It appears to act more selectively on the a2-δ subunits of calcium channels in the brain than gabapentin. Pregabalin was approved by the FDA in late 2004 for the treatment of neuropathic pain and epilepsy. In 2008, it became the first drug approved for the treatment of fibromyalgia. Although pregabalin was approved in the European Union in 2006 for the treatment of generalized anxiety disorder, at the time of writing, the FDA has not approved pregabalin for use in generalized anxiety disorders in the United States. Because of the consistent efficacy of pregabalin in clinical trials and the known safety profile in clinical experience, it is not entirely clear what is preventing the approval of pregabalin for the treatment of generalized anxiety disorder. There have been reports that the risk-benefit ratio of the drug is worrying given the hepatotoxicity that occurs in micc, but this has not been proven to be a problem after human release. Pregabalin is classified as an anticonvulsant and analgesic. The drug is currently under review by the FDA. Pregabalin has the potential for abuse and misuse. Pregabalin is classified as a Class V compound in the United States.